Mark Niciu

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, Mark Niciu sits in the upper half of US sponsors by registered trial count (#4,885 of 15,742 sponsors by registered trial count).

2 total trials 2 currently recruiting early-phase tilt upper half by trial count

Mark Niciu: 2 sponsored US clinical trials, 2 recruiting.

Mark Niciu sponsors 2 registered US clinical trials on ClinicalTrials.gov, 2 of them currently recruiting. 0 of these trials are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Major Depression, with 2 trials.

Mid-pack sponsor footprint

Mark Niciu is in the upper half of sponsors by trial count (#4,885 of 15,742 sponsors by registered trial count). Use the pipeline list and therapeutic areas to see what drives that mid-pack volume.

Open and recent trials

2 total, page 1 of 1

RECRUITING

University of Iowa Interventional Psychiatry Service Patient Registry

NCT04480918
RECRUITING Phase 2

Ketamine Alcohol (in Treatment-Resistant Depression)

NCT02122562

Phase Distribution

PhaseTrial count
Phase 2 1

Therapeutic Areas

Major Depression 2
Major Depressive Episode 1
Alcoholism 1
Magnetic Resonance Imaging 1
Obsessive - Compulsive Disorder 1
Treatment-Resistant Depression 1
Bipolar Disorder 1
Bipolar Depression 1
Major Depressive Disorder 1

What is open in the Mark Niciu pipeline

2 recruiting of 2 indexed (100% open).

Phase mix: 0 late (III/IV) vs 1 early (I/II) (early-phase heavy).

Top condition: Major Depression (2 trials), 8 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Mark Niciu: open-pipeline peers nationwide

Peers matched on 2 registered trials and 100% open enrollment, not the therapeutic-area sidebar.

Mark Niciu sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 1.522.533.544.5 0%50%100%150% Total trials Recruiting share Mark Niciu1200 Pharma1ST Biotherapeutics3 Waves Wellness3EO HealthAAVantgarde Bio SrlAcorn BiolabsAcrivon TherapeuticsADARx Pharmaceuticals
Mark Niciu sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Mark Niciu sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 2 trials (± recruiting share)

Sponsors near 100% open enrollment (± trial volume)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Mark Niciu page

2 registered trials is a research-attention snapshot, not an endorsement of Mark Niciu or any single study.

  • 2 of Mark Niciu's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Major Depression is the condition Mark Niciu studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Major Depression trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Mark Niciu pipeline card: 2 registered trials from official public datasets.Report a data error.